Should I Buy ATYR? ATYR 2026 Analysis

Should You Buy aTyr Pharma Inc (ATYR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.850

1 Day change

26.11%

52 Week Range

7.290

Analysis Updated At

2026/01/28

ATYR is not a good buy right now for a beginner long-term investor deploying $50k–$100k who wants to act immediately. The chart trend is still bearish (major moving averages stacked bearishly), there are no proprietary buy signals today, and the company remains a high-risk microcap biotech with very limited revenue and ongoing losses. Insider buying is a positive, but it’s not enough to offset weak trend/visibility for a long-term beginner entry today.

Technical Analysis

Price/Trend: Pre-market ~$0.69 (-2.40%), trading below the pivot (0.712). Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating the dominant trend remains down. Momentum: MACD histogram is slightly positive (0.00276) but contracting, suggesting any bounce is weakening. RSI(6) ~44.4 (neutral-to-slightly weak), not signaling an oversold reversal. Levels: Near-term support at S1 ~0.675 (then S2 ~0.653). Resistance levels to reclaim are ~0.748 (R1) and ~0.771 (R2). With price below pivot and bearish MA structure, risk of revisiting support is elevated versus a clean breakout.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment read: Open interest put/call at 0.18 is call-heavy (positioning skews bullish), but today’s put/call volume at 3.43 shows near-term traders are buying puts/hedges aggressively (more bearish/defensive flow intraday). Volatility: 30D IV ~205.95 vs HV ~95.05 indicates options are pricing very large moves; this is typical speculative/biotech-style risk and is not ideal for a beginner long-term ‘buy now’ decision. Volume is elevated (today vs 30D avg ~107%), confirming active speculation/hedging.

Technical Summary

Sell

Buy

Positive Catalysts

1) Insider activity: Insiders are buying, with buying amount up ~5978.67% over the last month (strong confidence signal). 2) Financial trend improvement: Losses narrowed YoY and EPS improved in the latest quarter (2025/Q3). 3) Options open interest skew: Very low OI put/call ratio (0.18) suggests longer-dated positioning is more bullish than bearish.

Neutral/Negative Catalysts

2) No near-term news catalysts: No news in the recent week, so there’s no clear event-driven driver to reverse trend immediately. 3) Business/earnings visibility: Revenue is extremely small (~$190k in 2025/Q3) and the company is still deeply unprofitable, making long-term outcomes highly uncertain. 4) Options flow today is defensive: Put-heavy option volume (put/call volume 3.43) implies traders are leaning cautious near-term.

Financial Performance

Latest quarter: 2025/Q3. Revenue was ~$190,000 (flat YoY, indicating limited commercial scale). Net income improved YoY to -$25.744M (about 49.16% improvement), and EPS improved to -$0.26 (about 13.04% improvement). Gross margin reported at 100% (likely reflecting the nature of small revenue/recognition rather than a scaled operating business). Overall: losses are narrowing, but the company is still far from profitability and revenue traction is minimal.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so a recent trend cannot be confirmed here. Without Wall Street consensus updates, there’s no clear external validation/catalyst from ratings momentum. Based on the provided fundamentals/technical setup, the ‘pro’ case would hinge on pipeline/insider confidence and a turnaround, while the ‘con’ case is the persistent high-risk profile (microcap biotech, limited revenue, ongoing losses) and bearish chart structure.

4 Analyst Rating

Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 7.33 USD with a low forecast of 1 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

3 Hold

0 Sell

Hold

Current: 0.674

Low

Averages

7.33

High

Current: 0.674

Low

Averages

7.33

High

Leerink

Faisal Khurshid

Outperform

maintain

$NULL

AI Analysis

2025-09-15

Reason

Leerink

Faisal Khurshid

Price Target

$NULL

AI Analysis

2025-09-15

maintain

Outperform

Reason

Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

2025-09-15

Reason

Cantor Fitzgerald

Price Target

2025-09-15

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATYR

Unlock Now

ATYR Should I Buy

ATYR Should I Buy

Should You Buy aTyr Pharma Inc (ATYR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch